Loading...
DOCUMENTS
21
NOTICES
32
MOTS CLES
Acceptability
Stricture
Alkylating agents
MICROBIOTA
Microbiota
Methylation
Immunosuppressant
Tuberculosis
Survival
Cost effectiveness
Patient-reported outcome
IL12
MARKER
Microbiote
Rituximab plus chlorambucil
Patients experience
Disease Progression
Monitoring
Colorectal cancer
Gene methylation
Rituximab
Upper gastrointestinal tract
Ulcerative colitis
Therapeutics
DNA METHYLATION
Méthylation
Epigenetics
MORTALITY
Drug
MALT
Contraindication
Heart disease risk factors
Primary sclerosing cholangitis
Cell adhesion
Inflammatory Bowel Diseases
Crohn's disease
Colon cancer
RISK
Biomarker
Bactéries
Fecal microbiota
Consensus
Vedolizumab
CARCINOGENESIS
IBD
Safety
Maintenance therapy
Inclusion
Venous thromboembolism
Thérapie ciblée
Small molecules
Gènes
Genes
Endoscopic treatment
Tailored therapy
Parvimonas micra
Epigénétiques
PCR
DNA methylation
Clinical trial
Screening
Resistance
Disease progression
Inflammatory bowel disease
Intestinal crypts
Colon
Biologics
COLON-CANCER
Surgery
Kidney diseases
Helicobacter pylori
Inflammatory bowel diseases
18 FDG-PET/CT
T1118 translocation
Eradication
Gene expression
HIV
Disability
Over 80s
Eligibility
Algorithm
Colectomy
Bacteria
Anti-TNF agents
Dysbiose
Immune cells
Crohn’s disease
Dysbiosis
Original Article Clinical
Anti-TNF
Cancer
Colorectal cancer Colibactin and lipids
Neoadjuvant chemotherapy
IL23
Clinical guidelines
Inhibitor
Résistance
Effectiveness
Colonic epithelial primary cells
Ustekinumab
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|